Literature DB >> 24919806

Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling.

L Eder-Azanza1, D Navarro1, P Aranaz1, F J Novo1, N C P Cross2, J L Vizmanos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24919806     DOI： 10.1038/leu.2014.190

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Structure of the molecular chaperone prefoldin: unique interaction of multiple coiled coil tentacles with unfolded proteins.

Authors:  R Siegert; M R Leroux; C Scheufler; F U Hartl; I Moarefi
Journal:  Cell       Date:  2000-11-10       Impact factor: 41.582

2.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

3.  Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

Authors:  A Tefferi; T L Lasho; C Finke; A A Belachew; E A Wassie; R P Ketterling; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 4.  Calreticulin: one protein, one gene, many functions.

Authors:  M Michalak; E F Corbett; N Mesaeli; K Nakamura; M Opas
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

6.  The structure of calreticulin C-terminal domain is modulated by physiological variations of calcium concentration.

Authors:  Ana María Villamil Giraldo; Máximo Lopez Medus; Mariano Gonzalez Lebrero; Rodrigo S Pagano; Carlos A Labriola; Lucas Landolfo; José M Delfino; Armando J Parodi; Julio J Caramelo
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

Review 7.  The role of structural disorder in the function of RNA and protein chaperones.

Authors:  Peter Tompa; Peter Csermely
Journal:  FASEB J       Date:  2004-08       Impact factor: 5.191

Review 8.  Calreticulin and cancer.

Authors:  Mohammadreza Zamanian; Abhi Veerakumarasivam; Syahril Abdullah; Rozita Rosli
Journal:  Pathol Oncol Res       Date:  2013-02-08       Impact factor: 3.201

9.  Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca(2+): some mechanistic and therapeutic implications.

Authors:  V Shivarov; M Ivanova; R V Tiu
Journal:  Blood Cancer J       Date:  2014-02-21       Impact factor: 11.037

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
View more
  11 in total

Review 1.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

2.  Constitutional genetic association with CALR mutations?

Authors:  L Eder-Azanza; P Evans; C Wickham; S Akiki; J L Vizmanos; A Chase; N C P Cross
Journal:  Leukemia       Date:  2015-07-22       Impact factor: 11.528

3.  The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants.

Authors:  Ayalew Tefferi; Terra L Lasho; Alexander Tischer; Emnet A Wassie; Christy M Finke; Alem A Belachew; Rhett P Ketterling; Curtis A Hanson; Animesh D Pardanani
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

4.  Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.

Authors:  Katte Rao Toppaldoddi; Maira da Costa Cacemiro; Olivier Bluteau; Barbara Panneau-Schmaltz; Amélie Pioch; Delphine Muller; Jean-Luc Villeval; Hana Raslova; Stefan N Constantinescu; Isabelle Plo; William Vainchenker; Caroline Marty
Journal:  Oncogene       Date:  2018-10-19       Impact factor: 9.867

5.  Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms.

Authors:  William Vainchenker; Isabelle Plo; Mira El-Khoury; Xénia Cabagnols; Matthieu Mosca; Gaëlle Vertenoeil; Christophe Marzac; Fabrizia Favale; Olivier Bluteau; Florence Lorre; Amandine Tisserand; Graciela Rabadan Moraes; Valérie Ugo; Jean-Christophe Ianotto; Jerôme Rey; Eric Solary; Lydia Roy; Philippe Rameau; Najet Debili; Florence Pasquier; Nicole Casadevall; Caroline Marty; Stefan N Constantinescu; Hana Raslova
Journal:  Oncogene       Date:  2020-06-22       Impact factor: 9.867

Review 6.  Mutant Calreticulin in the Myeloproliferative Neoplasms.

Authors:  Daniel Prins; Carlos González Arias; Thorsten Klampfl; Jacob Grinfeld; Anthony R Green
Journal:  Hemasphere       Date:  2020-01-15

Review 7.  Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.

Authors:  David M Ross; Jeffrey J Babon; Denis Tvorogov; Daniel Thomas
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

8.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Authors:  D Pietra; E Rumi; V V Ferretti; C A Di Buduo; C Milanesi; C Cavalloni; E Sant'Antonio; V Abbonante; F Moccia; I C Casetti; M Bellini; M C Renna; E Roncoroni; E Fugazza; C Astori; E Boveri; V Rosti; G Barosi; A Balduini; M Cazzola
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

9.  CALR mutation characterization in myeloproliferative neoplasms.

Authors:  Cristina Bilbao-Sieyro; Yanira Florido; María Teresa Gómez-Casares
Journal:  Oncotarget       Date:  2016-08-16

Review 10.  Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.

Authors:  Salem H Alshemmari; Reshmi Rajan; Ashkan Emadi
Journal:  Med Princ Pract       Date:  2016-09-21       Impact factor: 1.927
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.